Surface Oncology, Inc. (SURF) financial statements (2021 and earlier)

Company profile

Business Address 50 HAMPSHIRE STREET, 8TH FLOOR
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments175105159
Cash and cash equivalents1754783
Short-term investments 5876
Receivables300
Prepaid expense325
Other undisclosed current assets  1
Total current assets:181108165
Noncurrent Assets
Operating lease, right-of-use asset2815
Property, plant and equipment778
Restricted cash and investments221
Other noncurrent assets000
Total noncurrent assets:37249
TOTAL ASSETS:217132174
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities777
Accounts payable233
Accrued liabilities001
Employee-related liabilities533
Deferred revenue 5
Debt63 
Deferred rent credit  0
Contract with customer, liability15
Other liabilities111
Other undisclosed current liabilities435
Total current liabilities:181927
Noncurrent Liabilities
Long-term debt and lease obligation4422 
Long-term debt, excluding current maturities155 
Operating lease, liability2917
Liabilities, other than long-term debt 3444
Deferred revenue 34
Contract with customer, liability39
Deferred rent credit  5
Total noncurrent liabilities:445644
Total liabilities:617571
Stockholders' equity
Stockholders' equity attributable to parent15657103
Common stock000
Additional paid in capital218178170
Accumulated other comprehensive income (loss) 0(0)
Accumulated deficit(62)(122)(67)
Total stockholders' equity:15657103
TOTAL LIABILITIES AND EQUITY:217132174

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:1261559
Operating expenses(65)(73)(69)
Operating income (loss):62(57)(9)
Nonoperating income
(Investment Income, Nonoperating)
010
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(2)2 
Income (loss) before gain (loss) on sale of properties:59(55)(9)
Other undisclosed net income (loss)(0) 2
Net income (loss) attributable to parent:59(55)(7)
Preferred stock dividends and other adjustments  (0)
Net income (loss) available to common stockholders, basic:59(55)(7)
Interest on convertible debt0  
Net income (loss) available to common stockholders, diluted:60(55)(7)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net income (loss):59(55)(7)
Comprehensive income (loss):59(55)(7)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00
Comprehensive income (loss), net of tax, attributable to parent:59(55)(6)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: